Cantor Fitzgerald Downgrades Oramed Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $5 From $20
Cantor Fitzgerald Downgrades Oramed Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $5 From $20
坎托·菲茨杰拉德将Oramed Pharmicals的评级从增持下调至中性，将目标价从20美元调整至5美元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册